In obesity mouse model, administration of the IL-6 receptor (IL-6R) inhibitor tocilizumab (TCZ) has been shown to significantly mitigate weight gain, regulate adipose tissue hypertrophy, enhance insulin sensitivity, and promote improved glucose tolerance (21). The gene discussed is IL6R; the disease is obesity disorder.